Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033431 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05033431 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT05033431, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase I, single-centre, open-label, parallel-group, single dose study to evaluate the pharmacokinetics, safety and tolerability of Brazikumab in healthy male and female Chinese participants and healthy male and female White participants.
Interventions
- DRUG Brazikumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05033431
The ClinicalTrials.gov registry entry for NCT05033431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brazikumab is the first listed.
NCT05033431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05033431 about?
NCT05033431 is a clinical study titled "Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants". This is a Phase I, single-centre, open-label, parallel-group, single dose study to evaluate the pharmacokinetics, safety and tolerability of Brazikumab in healthy male and female Chinese participants and healthy male and female White participants.
What is the current status of trial NCT05033431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-10-11. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT05033431?
The interventions under investigation include: Brazikumab (DRUG).
Who is sponsoring clinical trial NCT05033431?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.